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Background: The aim of this study was to clarify retrospectively the characteristics of chil-
dren  hospitalized for respiratory tract infection caused by macrolide-resistant Mycoplasma
pneumoniae  (M. pneumoniae).
Methods:  Children who were hospitalized for respiratory tract infection due to M. pneumo-
niae  were enrolled in this study. The diagnosis of M. pneumoniae infection was made on the
grounds  of polymerase chain reaction results.
Results: Thirty-three children were hospitalized due to lower respiratory tract infection with
M. pneumoniae. Of the 33 children, 31 (median age ﬁve years) were identiﬁed as being infected
with  macrolide-resistant M. pneumoniae (A2063G:30, A2064G:1) by sequence analysis. Of the
31 children infected with macrolide-resistant M. pneumoniae, 21 (68%) had received 14- or
15-membered  macrolide antibiotics and four (13%) had received minocycline before hos-
pitalization.  During hospitalization, minocycline was administered to 16 (52%) of the 31
children  infected with macrolide-resistant M. pneumoniae. Of the 20 children infected with
macrolide-resistant  M. pneumoniae under eight years of age, six (30%) were treated with
minocycline  during hospitalization. The difference in total febrile days between children
receiving  minocycline treatment before hospitalization and children not receiving minocy-
cline  treatment was three days.
Conclusions: The majority of hospitalized children with respiratory tract infection due to
macrolide-resistant  M. pneumoniae infection was of preschool age and had received 14-
or 15-membered macrolide antibiotics before hospitalization. Because macrolide-resistantM.  pneumoniae is widespread in Japan, the administration of minocycline as a second-lineantibiotic  in children und
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ntroduction
ycoplasma pneumoniae (M. pneumoniae) is a major cause
f  respiratory infection in school-age children and young
dults.  Because M. pneumoniae is sensitive to macrolides (14-
embered  ring: erythromycin, clarithromycin; 15-membered
ing:  azithromycin), M. pneumoniae illness is usually mild,
nd  hospitalization is infrequently required. Since 2000,
owever, the emerging of macrolide-resistant M. pneumo-
iae  has been reported in Japan, China, United States,
nd  European countries, and recently, adults and children
ave  been suffering from macrolide-resistant M.  pneumo-
iae  infections.1–12 Macrolide resistance rates in children
ith respiratory tract infection due to M. pneumoniae were
eported  to be 30.6% in Japan and 9.8% in France.4,6–8,10
he emergence of macrolide-resistant M.  pneumoniae changes
he  clinical courses of children with respiratory tract infec-
ion.
Tetracyclines and ﬂuoroquinolones can be used for the
reatment of M.  pneumoniae infections;13 however, these drugs
re  not recommended in children due to concerns about possi-
le  adverse effects. One of the adverse effects of tetracyclines
s  incorporation into tissues that are calcifying at the time
f  administration. Incorporation of tetracyclines into teeth,
artilage,  and bone results in permanent discoloration vary-
ng  from yellow to brown.14–18 Because the calciﬁcation of
ermanent teeth is not completed until 7–8 years of age,
etracyclines are not indicated for the treatment of common
nfection in children under eight years of age.19,20 In addition,
uoroquinolones have the potential to induce joint/cartilage
oxicity in the pediatric population.21–23 Therefore, macrolides
ave  been considered as ﬁrst-line drugs for the treatment of
.  pneumoniae infections in children.
The aim of this study was  to clarify retrospectively the
haracteristics of children hospitalized for respiratory tract
nfection  caused by macrolide-resistant M. pneumoniae in
 regional hospital in Japan, where macrolide-resistant M.
neumonia  infections are endemic. In addition, we ana-
yzed  the treatment options for macrolide-resistant M.
neumoniae infections in young children under eight years
f  age.
atients  and  methods
atients
hildren who were  hospitalized in Eastern Yokohama Hospi-
al  between September 2010 and February 2012 for respiratory
ract  infection due to M. pneumoniae were  enrolled in this study.
ll  of them were  diagnosed with pneumoniae or bronchitis
n  the basis of chest X-ray ﬁndings. The diagnosis of M.  pneu-
oniae  infection was  made on the grounds of PCR results of
asopharyngeal or throat material collected with a swab. A
ebrile day was  deﬁned as a day in which the child’s body tem-
◦erature  exceeded 38.0 C at least once. Clinical information
as  collected from medical records at Eastern Yokohama Hos-
ital.  Informed written consent for study participation was
btained  from all of the children’s parents or guardians. The4;1 8(3):294–299  295
study protocol was approved by the ethics committee of East-
ern  Yokohama Hospital (2012041) and conformed to the ethical
guidelines  of the Declaration of Helsinki.
PCR  assay
Nasopharyngeal or throat swabs collected from patients were
vigorously  mixed with 500 L of PBS. Of the 500 L, 200 L
was  used for the extraction of M.  pneumoniae DNA,  which was
accomplished using QIAamp DNA Blood Mini kit (QIAGEN,
Hilden, Germany) according to the manufacturer’s instruc-
tions.  The extracted DNA was dissolved in 100 L of elution
buffer  and stored at −30 ◦C. PCR assays were  performed as
described  by Abele-Horn et al.24 In brief, PCR was  performed
in  a 50 L reaction mixture containing 2.5 U of Taq DNA  poly-
merase  (TaKaRa EX Taq, Takara Bio, Shiga, Japan) with 0.2 M
primers  and 10 L extracted DNA. The ampliﬁcation was per-
formed  for 40 cycles (denaturation at 94 ◦C for 30 s, annealing
at  55 ◦C for 30 s, and extension at 72 ◦C for 45 s) with a sense
primer (MP-1: 5′-GAA GCT TAT GGT ACA GGT TGG-3′) and
an  antisense primer (MP-2: 5′-ATT ACC ATC CTT GTT GTA
AGG-3′). PCR assay was  performed in a GeneAmp PCR sys-
tem  9700 (Applied Biosystems, Foster City, CA). The ampliﬁed
PCR  product was  a 144-bp DNA fragment of the M. pneumoniae
ATPase  operon gene. A product of the predicted size (272 bp)
was  observed after electrophoresis on a 2% agarose gel, ethid-
ium  bromide staining, and visualization under ultraviolet
light.
Sequence  analysis  of  the  23S  rRNA  gene
To identify the mutations of domain V of 23S rRNA, we  per-
formed  nested PCR as previously described by Matsuoka et al.5
The ﬁrst-round PCR product (927 bp) was obtained using an
outer  sense primer (MN23SDVF; 5′-GCAGTGAAGAACGAGGGG-
3′ [1758–1775]) and an outer antisense primer (MN23SDVR;
5′-GTCCTCGCTTCGGTCCTCTCG-3′ [2664–2684]). To detect the
point  mutation at 2063 and 2064 in domain V, we  used an inner
sense  primer (MN23SF1937; 5′-ACTATAACGGTCCTAAGGTA-3′
[1918–1937]) and an inner antisense primer (MN23SR2128; 5′-
ACCTATTCTCTACATGATAA-3′ [2108–2177]) for a second-round
ampliﬁcation, and a 210-bp PCR product was  obtained. For
the  detection of point mutation at 2617 in domain, the inner
sense  primer (MN23SF2577; 5′-TACGTGAGTTGGGTTCAAA
[2577–2595]) and antisense primer (MN23SR2664; 5′-
GTCCTCGCTTCGGTCCTCTCG-3′ [2664–2684]) were  used
for  a second round ampliﬁcation, and a 108-bp PCR product
was  obtained. Nucleotide positions were  designated on
the  basis of nucleotide sequences from M.  pneumonia M129
(GenBank/EMBL accession number X68422). A product of the
predicted  size was  observed after electrophoresis on a 2%
agarose  gel, ethidium bromide staining, and visualization
under ultraviolet light. The DNA band was  excised from
the  gel, and the DNA was puriﬁed using a QIAquick gel
extraction and DNA puriﬁcation kit (Qiagen, Hilden, Ger-
many).  All sequencing reactions were performed using the
ABI  Prism Big Dye Terminator Cycle Sequencing kit (Applied
Biosystems).
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Table 1 – Patient characteristics of hospitalized children infected with macrolide-resistant Mycoplasma pneumonia.
Male/female 14/17
Age (yr.) Median  (range) 5 (1–15)
Mean  6.2
White blood cell counts (/L) Median  (range) 6520 (3410–15,570)
Mean  6913
Serum C-reactive protein levels (mg/dL) Median  (range) 2.5 (0.3–12.6)
Mean  3.4
Number of days with fever before hospitalization Median  (range) 6 (3–11)
Mean  6.1
No. of patients prescribed 14- or 15-membered macrolide
antibiotics before hospitalization
21  (68%)
Days of administration of 14-membered
macrolide  antibiotics before
hospitalization  (n = 11)
Median (range) 3 (2–5)
Mean  3.3
No. of patients prescribed minocycline before hospitalization 3 (10%)
Days of administration of minocycline before
hospitalization (n = 3)
Median (range) 3 (2–6)
Mean  3.7
Mutations in 23S rRNA gene A2063G  30Results
Patients  infected  with  macrolide-resistant  M.  pneumoniae
Between September 2010 and February 2012, 33 children
(male/female = 16/17, age range 1–15 years, median age ﬁve
years)  hospitalized for respiratory tract infection were  diag-
nosed  with M. pneumoniae infection by PCR assay. The
nucleotide sequence analysis of the 23S rRNA gene of M.
pneumoniae showed that 31 children (94%) were  infected with
macrolide-resistant M.  pneumoniae and the remaining two chil-
dren (6%) were  infected with wild-type M.  pneumoniae. The
mutations  of A2063G and A2064G were  detected in 30 chil-
dren  and in one child, respectively. The mutation of C2617G
was  not detected in any of the children.
Patients’ characteristics of the 31 children with macrolide-
resistant M.  pneumoniae at the ﬁrst day of hospitalization
Table 2 – Antimicrobial agents against macrolide-resistant Myc
Under
-Lactam → clarithromycin 
-Lactam → azithromycin
Clarithromycin → azithromycin 
Clarithromycin → minocycline 
Tosuﬂoxacin 
-Lactam 
Azithromycin 
Clarithromycin 
Clarithromycin → azithromycin → tosuﬂoxacin 
-Lactam → erythromycin 
-Lactam → josamycin 
-Lactam → minocycline 
Norﬂoxacin → rokitamycine
Minocycline 
No antibiotics A2064G  1
C2617G  0
are shown in Table 1. Febrile days before hospitalization
ranged from three to 11, with a median of six. Of the 31
children  infected with macrolide-resistant M.  pneumoniae, 30
(97%)  were treated with antibiotics as shown in Table 2. Of
the  31 children infected with macrolide-resistant M. pneu-
moniae,  21 (68%) had a history of receiving erythromycin,
clarithromycin, or azithromycin. The duration of administra-
tion  of 14-membered macrolides ranged from two to ﬁve days,
with  a median of three days. Four of the children had a history
of  receiving minocycline before hospitalization. Of the four
children  administered with minocycline, three were  under
eight  years of age (Table 2).
Treatment  of  macrolide-resistant  M.  pneumoniae  infection
during  hospitalization
The antibiotics administered during hospitalization to
the  children in this study are shown in Table 3. As initial
oplasma pneumoniae used before hospitalization.
 8 years of age (n = 20) 8 years old or older (n = 11)
3 2
1  2
2 1
2 0
2 0
2 2
2 1
1 1
1 0
1 0
1 0
1 0
1  0
0 1
0 1
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Table 3 – Antimicrobial agents against macrolide-resistant Mycoplasma pneumoniae duration hospitalization.
Under 8 years of age (n = 20) 8 years old or older (n = 11)
Minocycline 5 10
Tosuﬂoxacin 4 0
Azithromycin 2 1
Clarithromycin 2 0
Clindamycin hydrochloride 2 0
Azithromycin → tosuﬂoxacin 2 0
Azithromycin → minocycline 1 0
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No antibiotics 
ntibiotics during hospitalization, minocycline was  adminis-
ered  to 15 children, azithromycin to six children, tosuﬂoxacin
quinolone) to four children, clarithromycin to two children,
lindamycin to two children, and clarithromycin plus
lindamycin to one child. One child did not receive any
ntimicrobial agents during hospitalization. Of the 11 chil-
ren  who  were  aged eight or more,  10 (91%) were treated with
inocycline  as the initial antibiotic during hospitalization.
n four of the 20 children under eight years of age, the initial
ntibiotics were  switched to other antimicrobial agents during
ospitalization. As second antibiotics during hospitalization,
inocycline was  administered to one child and tosuﬂoxacin
o  three children. The initial antibiotics were not changed in
ny children who were over 8 years of age.
valuation  of  the  effectiveness  of  minocycline
o evaluate the effectiveness of minocycline, we compared
he  number of febrile days among the children administered
inocycline before hospitalization, the children administered
inocycline during hospitalization (excepting the children to
hom minocycline was  administered before hospitalization),
nd  the children who did not receive minocycline (Table 4).
here  was  no difference in the number of days with fever
efore  hospitalization (median from 6 to 6.5 days) among
he  three groups. The number of days with fever during
ospitalization ranged from 0 to 1 (median 0.5 day) among
Table 4 – Days with fever of patients infected with macrolide-re
Minocyc
administered
hospitaliz
(n  = 4)
Age (yr.) Median  (range) 4.5 (4–
Mean 6.0 
No. of patients prescribed
14-  or 15-membered
macrolide antibiotics
before  hospitalization
2  (50%
Days with fever before
hospitalization
Median  (range) 6.5 (5–
Mean 6.5 
Days with fever during
hospitalization
Median  (range) 0.5 (0–
Mean 0.5 
Total days with fever Median  (range) 7 (6–8)
Mean 7 1 0
1 0
children  who received minocycline before hospitalization. In
the children who received minocycline during hospitaliza-
tion,  the number of days with fever during hospitalization
ranged from one to ﬁve (median two days). On the other
hand,  the number of days with fever during hospitalization
ranged from zero to seven (median four days) in children
who  did not receive minocycline. Similarly, the median of
total  number of days with fever in children who  received
minocycline was  3-day lower than that in children who
had  not received minocycline. These ﬁndings suggest that
minocycline contributed to a 3-day-earlier resolution of fever
in  children infected with macrolide-resistant M.  pneumoniae.
Clinical  manifestations  in  children  with
macrolide-resistant  M.  pneumoniae  infection
All 31 children infected with macrolide-resistant M. pneumo-
niae  had cough and dyspnea. The pulsed oxygen saturation
ranged from 86% to 98% (median 93%). Of  the 31 children, 21
(65%)  required oxygen supplementation due to hypoxia during
hospitalization. None of them required mechanical ventila-
tion.  All of them were cured without consequences.Discussion
Of the 33 hospitalized children with respiratory tract infec-
tion  caused by M. pneumonia, 31 (94%) were  infected with
sistant Mycoplasma pneumonia.
line
 before
ation
Minocycline
administered  during
hospitalization
(n  = 12)
Minocycline not
administered (n = 15)
11) 8.5 (3–15) 4 (1–11)
8.6 4.3
) 9 (75%) 9 (60%)
8) 6 (5–9) 6 (3–11)
6.1 6.1
1) 2 (1–5) 4 (0–7)
2.6 4.3
 8.5 (6–11) 10 (6–16)
8.5 10.3
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macrolide-resistant M. pneumonia. Usually, the peak incidence
of  M.  pneumoniae occurs in school-aged children and young
adults.  In this study, however, the median age of the 31 chil-
dren  infected with macrolide-resistant M. pneumoniae was
ﬁve  years of age. Of these 31 children, 21 (68%) had already
been  treated with 14- or 15-membered macrolide antibiotics
before  admission. In addition, fever had persisted for six
days  (median) before admission in the 31 children infected
with  macrolide-resistant M. pneumoniae. These ﬁndings sug-
gest  that the majority of hospitalized children suffering from
M.  pneumoniae infection in Japan are infected with macrolide-
resistant strains and pre-school children are likely to show
persistent  clinical symptoms such as high fever and cough
even  if macrolide antibiotics are administered in case of
macrolide-resistant M. pneumoniae.
The total number of days with fever in children infected
with  macrolide-resistant M. pneumoniae in this study was
comparable with that reported in a previous study, which
showed  a median of 10 days.25 The authors of the previous
study reported a median of 3.5 days with fever during 14-
membered ring macrolides administration in patients with
macrolide-resistant M.  pneumoniae infection, indicating that
four  days of administration of macrolides is sufﬁcient to con-
trol  macrolide-resistant M. pneumoniae infection. However, the
present  study showed that children infected with macrolide-
resistant M.  pneumoniae had already received 14-membered
macrolide antibiotics for three days (median) before hospi-
talization  and high fever persisted during hospitalization
even with continuing use of macrolides. These ﬁndings
suggest that it takes four days or more  for the treatment
with macrolide antibiotics to control macrolide-resistant M.
pneumoniae  infection.
There  are currently two choices for pediatricians to treat
hospitalized children infected with macrolide-resistant M.
pneumoniae.  One is to continue to use macrolide antibiotics
and  waiting for the resolution of clinical symptoms, because
fatal  outcome of M.  pneumoniae infection is rare. The other
choice  is to discontinue macrolide antibiotics and try to use
tetracyclines or ﬂuoroquinolones. In this study,23 31 (74%)
children  infected with macrolide-resistant M. pneumoniae
received minocycline or tosuﬂoxacin during hospitalization.
These ﬁndings indicate that the majority of pediatricians
prefer to discontinue macrolide antibiotics during hospi-
talization. Minocycline has been reported to be effective
in  macrolide-resistant M. pneumoniae infection.4,9,11,26 The
present study showed that the difference in the number
of  days with fever during hospitalization between children
receiving pre-hospitalization minocycline treatment and chil-
dren not receiving minocycline treatment was  of three days.
Although  this was  a retrospective study and not a con-
trolled  study, these ﬁndings indicate that the early treatment
with  minocycline was  effective against macrolide-resistant
M. pneumoniae infection in children. In the case of the young
child  with respiratory failure described above, the admin-
istration of minocycline was  required to improve clinical
symptoms.Of  the 16 children treated with minocycline before or
during  hospitalization, two (four years old, 11 years old)
received  minocycline as ﬁrst-line antimicrobial agent, while
the  remaining children received minocycline as second-line 1 4;1  8(3):294–299
microbial agent through their clinical courses. Of the 11 chil-
dren  who were aged eight years or older, 10 (91%) were
treated with minocycline during hospitalization. Although
minocycline is contraindicated or not indicated in children
under  eight years of age, six (38%) of the 16 children treated
with  minocycline were under eight years in this study. The
prevalence  of tetracycline and minocycline tooth staining
was  reported to be approximately 3–6%.19 Moreover, there
are  some reports of minocycline-derivative tooth staining in
adults.14,15,27,28 However, the association between dose and
tooth  staining is controversial.19 In contrast, a previous study
reported  that there was  no signiﬁcant difference in dental
staining and defects between children under eight years of
age  treated with oral minocycline for brucellosis and matched
controls.29 Normally, minocycline should not be administered
as  a ﬁrst-line antimicrobial agent against M. pneumoniae infec-
tion  in young children. When minocycline is administered in
children under eight years of age after considering the bene-
ﬁts  and risks, it is essential to inform parents that minocycline
has  the potential to stain tooth.
Seven children treated with non-minocycline received
tosuﬂoxacin, which is a quinolone antibiotic. In 2010, tosu-
ﬂoxacin  was  approved for children by the Japanese Health and
Labor  Ministry. The antimicrobial mechanism of quinolone
is  different from that of macrolides,1,6,30–32 and tosuﬂoxacin
is considered by some clinicians to be effective against
macrolide-resistant M. pneumoniae infection. However, further
studies  are required to determine the effectiveness of tosu-
ﬂoxacin  in macrolide-resistant M.  pneumoniae infection.
In  conclusion, preschool children with lower respiratory
tract diseases due to macrolide-resistant M. pneumoniae infec-
tion  tend to be hospitalized. The majority of the children with
macrolide-resistant M.  pneumoniae infection in our study had
received  14- or 15-membered macrolide antibiotics before hos-
pitalization. The treatment with minocycline contributed to
the early resolution of clinical symptoms. Although minocy-
cline  should not be used as ﬁrst-line antimicrobial agent
in  children under eight years of age, minocycline could be
allowed  to be administered if the respiratory condition wors-
ens  during the administration of macrolide antibiotics.
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